BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33921360)

  • 21. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
    Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
    Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 23. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-IL-5 treatments in severe eosinophilic asthma: real life datas].
    Özdel Öztürk B; Bavbek S
    Tuberk Toraks; 2020 Jul; 68(2):148-159. PubMed ID: 32755115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
    Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
    Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 31. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
    Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
    Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
    Giannetti MP; Cardet JC
    Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab.
    Bergantini L; d'Alessandro M; Cameli P; Bianchi F; Sestini P; Bargagli E; Refini RM
    Int Arch Allergy Immunol; 2020; 181(10):746-753. PubMed ID: 32731216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
    Ramonell RP; Iftikhar IH
    Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
    Drick N; Seeliger B; Welte T; Fuge J; Suhling H
    BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.